{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:29:50Z","timestamp":1792074590496,"version":"4.4.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.neuropharm.2021.108588","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T11:26:43Z","timestamp":1619782003000},"page":"108588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration"],"prefix":"10.1016","volume":"191","author":[{"given":"Camille","family":"Taccola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Barneoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvaine","family":"Cartot-Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Schussler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Saubam\u00e9a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Chasseigneaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Cochois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Mignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8382-1493","authenticated-orcid":false,"given":"Emmanuel","family":"Curis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Lochus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Nicolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Dodacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cisternino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Decl\u00e8ves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanchon","family":"Bourasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","article-title":"Blood-brain barrier structure and function and the challenges for CNS drug delivery","volume":"36","author":"Abbott","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0022-510X(83)90157-0","article-title":"Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia","volume":"60","author":"Alafuzoff","year":"1983","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF00693782","article-title":"Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study","volume":"73","author":"Alafuzoff","year":"1987","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/jcbfm.2014.172","article-title":"Human apolipoprotein E varepsilon4 expression impairs cerebral vascularization and blood-brain barrier function in mice","volume":"35","author":"Alata","year":"2015","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.neuropharm.2021.108588_bib5","first-page":"1","article-title":"Fitting linear mixed-effects models using lme4.J","volume":"67","author":"Bates","year":"2015","journal-title":"Stat. Softw."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0197-4580(00)00121-4","article-title":"Agrin and microvascular damage in Alzheimer's disease","volume":"21","author":"Berzin","year":"2000","journal-title":"Neurobiol. Aging"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/cne.10186","article-title":"Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice","volume":"446","author":"Bian","year":"2002","journal-title":"J. Comp. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","article-title":"Lack of widespread BBB disruption in alzheimer's disease models: focus on therapeutic antibodies","volume":"88","author":"Bien-Ly","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2021.108588_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-015-0186-2","article-title":"Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy","volume":"3","author":"Blair","year":"2015","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0404.1990.tb01563.x","article-title":"Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors","volume":"81","author":"Blennow","year":"1990","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pneurobio.2005.06.004","article-title":"Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism","volume":"76","author":"Block","year":"2005","journal-title":"Prog Neurobiol"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.jnen.0000203077.53080.2c","article-title":"Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status","volume":"65","author":"Bouras","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/nan.12599","article-title":"Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP-43 pathology","volume":"46","author":"Bourassa","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.neuropharm.2009.01.006","article-title":"Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease","volume":"56","author":"Bourasset","year":"2009","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1083\/jcb.40.3.648","article-title":"Junctions between intimately apposed cell membranes in the vertebrate brain","volume":"40","author":"Brightman","year":"1969","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000017248","article-title":"White matter lesions in dementia: an MRI study on blood-brain barrier dysfunction","volume":"11","author":"Bronge","year":"2000","journal-title":"Dement. Geriatr. Cognit. Disord."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2990.2010.01139.x","article-title":"Review: cerebral microvascular pathology in ageing and neurodegeneration","volume":"37","author":"Brown","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108588_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nbd.2017.04.007","article-title":"NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration","volume":"104","author":"Brureau","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1176\/jnp.10.1.78","article-title":"Blood-brain barrier integrity in Alzheimer's disease patients and elderly control subjects","volume":"10","author":"Caserta","year":"1998","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108588_bib20","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/jcbfm.2008.34","article-title":"In situ mouse carotid perfusion model: glucose and cholesterol transport in the eye and brain","volume":"28","author":"Cattelotte","year":"2008","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.neuropharm.2021.108588_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2013.06.004","article-title":"Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies","volume":"108","author":"Chen","year":"2013","journal-title":"Prog Neurobiol"},{"issue":"16","key":"10.1016\/j.neuropharm.2021.108588_bib22","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.1021\/acs.jmedchem.8b01007","article-title":"Reevaluating the substrate specificity of the L-type Amino acid transporter (LAT1)","volume":"61","author":"Chien","year":"2018","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/bpa.12041","article-title":"Quantitative vascular pathology and phenotyping familial and sporadic cerebral small vessel diseases","volume":"23","author":"Craggs","year":"2013","journal-title":"Brain Pathol."},{"issue":"R1","key":"10.1016\/j.neuropharm.2021.108588_bib24","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1093\/hmg\/ddq160","article-title":"Molecular mechanisms of neurodegeneration in Alzheimer's disease","volume":"19","author":"Crews","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"41","key":"10.1016\/j.neuropharm.2021.108588_bib25","doi-asserted-by":"crossref","first-page":"10536","DOI":"10.1523\/JNEUROSCI.3133-06.2006","article-title":"p25\/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo","volume":"26","author":"Cruz","year":"2006","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0896-6273(03)00627-5","article-title":"Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles","volume":"40","author":"Cruz","year":"2003","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nut.2010.07.021","article-title":"Brain fuel metabolism, aging, and Alzheimer's disease","volume":"27","author":"Cunnane","year":"2011","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/bioinformatics\/bty629","article-title":"Determination of sets of covariating gene expression using graph analysis on pairwise expression ratios","volume":"35","author":"Curis","year":"2019","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00004647-200002000-00020","article-title":"Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice","volume":"20","author":"Dagenais","year":"2000","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108588_bib30","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1471-4159.2008.05720.x","article-title":"ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier","volume":"107","author":"Dauchy","year":"2008","journal-title":"J. Neurochem."},{"issue":"22","key":"10.1016\/j.neuropharm.2021.108588_bib31","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1073\/pnas.81.22.7233","article-title":"Identification and characterization of the glucose transporter of the blood-brain barrier by cytochalasin B binding and immunological reactivity","volume":"81","author":"Dick","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2021.108588_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.neuropharm.2014.02.010","article-title":"Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease","volume":"81","author":"Do","year":"2014","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JAD-150350","article-title":"Age-dependent regulation of the blood-brain barrier influx\/efflux equilibrium of amyloid-beta peptide in a mouse model of alzheimer's disease (3xTg-AD)","volume":"49","author":"Do","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-009-0532-1","article-title":"Classification and basic pathology of Alzheimer disease","volume":"118","author":"Duyckaerts","year":"2009","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0006-3223(90)90410-4","article-title":"Rapid dynamic CT scanning in primary degenerative dementia and age-matched controls","volume":"28","author":"Dysken","year":"1990","journal-title":"Biol. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s004010000195","article-title":"Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease","volume":"100","author":"Farkas","year":"2000","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00401-005-0007-y","article-title":"Age-related microvascular degeneration in the human cerebral periventricular white matter","volume":"111","author":"Farkas","year":"2006","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neurobiolaging.2007.07.015","article-title":"Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis","volume":"30","author":"Farrall","year":"2009","journal-title":"Neurobiol. Aging"},{"issue":"13","key":"10.1016\/j.neuropharm.2021.108588_bib39","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1073\/pnas.88.13.5779","article-title":"Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study","volume":"88","author":"Farrell","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.neuron.2005.10.033","article-title":"Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory","volume":"48","author":"Fischer","year":"2005","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108588_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF02279767","article-title":"Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF\/serum ratios of albumin and IgG","volume":"240","author":"Frolich","year":"1991","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neulet.2009.08.014","article-title":"In vivo down-regulation of mouse brain capillary P-glycoprotein: a preliminary investigation","volume":"464","author":"Fuest","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2021.108588_bib43","first-page":"428010","article-title":"Mechanism of oxidative stress in neurodegeneration","author":"Gandhi","year":"2012","journal-title":"Oxid Med Cell Longev"},{"issue":"44","key":"10.1016\/j.neuropharm.2021.108588_bib44","doi-asserted-by":"crossref","first-page":"15751","DOI":"10.1523\/JNEUROSCI.3588-11.2011","article-title":"Synaptic deficits are rescued in the p25\/Cdk5 model of neurodegeneration by the reduction of beta-secretase (BACE1)","volume":"31","author":"Giusti-Rodriguez","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108588_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-6606-3-12","article-title":"Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice","volume":"3","author":"Gu","year":"2010","journal-title":"Mol. Brain"},{"issue":"3\u20134","key":"10.1016\/j.neuropharm.2021.108588_bib46","first-page":"175","article-title":"Glucose transporter 1, distribution in the brain and in neural disorders: its relationship with transport of neuroactive drugs through the blood-brain barrier","volume":"43","author":"Guo","year":"2005","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.neuropharm.2021.108588_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","article-title":"Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy","volume":"143","author":"Gustafsson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108588_bib48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.neuropharm.2017.08.002","article-title":"Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology","volume":"128","author":"Gustafsson","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11095-018-2546-7","article-title":"Alzheimer's disease phenotype or inflammatory insult does not alter function of L-type Amino acid transporter 1 in mouse blood-brain barrier and primary astrocytes","volume":"36","author":"Gynther","year":"2018","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/jcbfm.2015.44","article-title":"Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease","volume":"36","author":"Halliday","year":"2016","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"5054","key":"10.1016\/j.neuropharm.2021.108588_bib117","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108588_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015697","article-title":"Loss of caveolin-1 accelerates neurodegeneration and aging","volume":"5","author":"Head","year":"2010","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib52","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2021.108588_bib53","doi-asserted-by":"crossref","first-page":"104645","DOI":"10.1016\/j.nbd.2019.104645","article-title":"Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: a translatable marker of synaptic degeneration","volume":"134","author":"Hoglund","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2021.108588_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2007.08.063","article-title":"Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP\/PS1 mice","volume":"1181","author":"Hooijmans","year":"2007","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00193951","article-title":"Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease","volume":"425","author":"Horwood","year":"1994","journal-title":"Virchows Arch."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib56","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1523\/JNEUROSCI.2642-12.2013","article-title":"Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy","volume":"33","author":"Iba","year":"2013","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib57","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3233\/JAD-170509","article-title":"In vivo visualization of tau accumulation, microglial activation, and brain atrophy in a mouse model of tauopathy rTg4510","volume":"61","author":"Ishikawa","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib58","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.ajpath.2011.06.025","article-title":"Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration","volume":"179","author":"Jaworski","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2021.108588_bib59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000049150","article-title":"Small vessel disease and Alzheimer's dementia: pathological considerations","volume":"13","author":"Kalaria","year":"2002","journal-title":"Cerebrovasc. Dis."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib60","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1471-4159.1989.tb07399.x","article-title":"Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease","volume":"53","author":"Kalaria","year":"1989","journal-title":"J. Neurochem."},{"issue":"37","key":"10.1016\/j.neuropharm.2021.108588_bib61","doi-asserted-by":"crossref","first-page":"23629","DOI":"10.1074\/jbc.273.37.23629","article-title":"Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98)","volume":"273","author":"Kanai","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.neuropharm.2021.108588_bib62","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJM198604103141506","article-title":"Alzheimer's disease","volume":"314","author":"Katzman","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib63","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","article-title":"The role of oxidative stress in neurodegenerative diseases","volume":"24","author":"Kim","year":"2015","journal-title":"Exp Neurobiol"},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108588_bib64","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","article-title":"Microglia: a sensor for pathological events in the CNS","volume":"19","author":"Kreutzberg","year":"1996","journal-title":"Trends Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108588_bib65","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","article-title":"Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI","volume":"32","author":"Landau","year":"2011","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0168-0102(99)00026-7","article-title":"Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain","volume":"34","author":"Lee","year":"1999","journal-title":"Neurosci. Res."},{"issue":"7113","key":"10.1016\/j.neuropharm.2021.108588_bib67","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib68","first-page":"183","article-title":"Early myoclonus and quasiperiodic EEG changes in non-familial Alzheimer's disease","volume":"1","author":"Mancardi","year":"1980","journal-title":"Ital. J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib69","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00692225","article-title":"Thickening of the basement membrane of cortical capillaries in Alzheimer's disease","volume":"49","author":"Mancardi","year":"1980","journal-title":"Acta Neuropathol."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108588_bib70","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/sj.npp.1300513","article-title":"Cytoskeletal genes regulation by chronic morphine treatment in rat striatum","volume":"29","author":"Marie-Claire","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0166-2236(00)01548-4","article-title":"Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders","volume":"23","author":"Mattson","year":"2000","journal-title":"Trends Neurosci."},{"issue":"5293","key":"10.1016\/j.neuropharm.2021.108588_bib72","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1126\/science.274.5293.1678","article-title":"Control of memory formation through regulated expression of a CaMKII transgene","volume":"274","author":"Mayford","year":"1996","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108588_bib73","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.neurobiolaging.2013.12.026","article-title":"Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP\/PS1 mice","volume":"35","author":"Minogue","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib74","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0197-4580(97)00111-5","article-title":"GLUT-1 expression in the cerebra of patients with Alzheimer's disease","volume":"18","author":"Mooradian","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2021.108588_bib75","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fnagi.2014.00251","article-title":"The cerebrovascular basement membrane: role in the clearance of beta-amyloid and cerebral amyloid angiopathy","volume":"6","author":"Morris","year":"2014","journal-title":"Front. Aging Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib76","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","article-title":"Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD","volume":"32","author":"Mosconi","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib77","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction","volume":"25","author":"Nation","year":"2019","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib78","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.bbadis.2015.12.016","article-title":"Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease","volume":"1862","author":"Nelson","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib79","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0896-6273(03)00259-9","article-title":"Cdk5 is a key factor in tau aggregation and tangle formation in vivo","volume":"38","author":"Noble","year":"2003","journal-title":"Neuron"},{"issue":"6762","key":"10.1016\/j.neuropharm.2021.108588_bib80","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/45159","article-title":"Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration","volume":"402","author":"Patrick","year":"1999","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib81","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1006\/nbdi.2001.0402","article-title":"Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease","volume":"8","author":"Poduslo","year":"2001","journal-title":"Neurobiol. Dis."},{"issue":"18","key":"10.1016\/j.neuropharm.2021.108588_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184616","article-title":"Norvaline restores the BBB integrity in a mouse model of alzheimer's disease","volume":"20","author":"Polis","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib83","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.bbrc.2016.09.053","article-title":"Dysregulation of neuronal calcium homeostasis in Alzheimer's disease - a therapeutic opportunity?","volume":"483","author":"Popugaeva","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib84","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190062","article-title":"The blood-brain barrier in health and disease: important unanswered questions","volume":"217","author":"Profaci","year":"2020","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib85","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.brainresrev.2005.03.002","article-title":"Glucose transport to the brain: a systems model","volume":"49","author":"Qutub","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"issue":"5733","key":"10.1016\/j.neuropharm.2021.108588_bib86","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.1113694","article-title":"Tau suppression in a neurodegenerative mouse model improves memory function","volume":"309","author":"Santacruz","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jcbfm.1987.1","article-title":"Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography","volume":"7","author":"Schlageter","year":"1987","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108588_bib116","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib88","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bpa.12004","article-title":"Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease","volume":"23","author":"Sengillo","year":"2013","journal-title":"Brain Pathol."},{"issue":"41","key":"10.1016\/j.neuropharm.2021.108588_bib89","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1523\/JNEUROSCI.0621-17.2017","article-title":"Inhibition of p25\/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia","volume":"37","author":"Seo","year":"2017","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib90","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/mp200129p","article-title":"Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels","volume":"8","author":"Shawahna","year":"2011","journal-title":"Mol. Pharm."},{"issue":"25","key":"10.1016\/j.neuropharm.2021.108588_bib91","doi-asserted-by":"crossref","first-page":"11794","DOI":"10.7150\/thno.44152","article-title":"Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease","volume":"10","author":"Shen","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JAD-160916","article-title":"TFP5, a peptide inhibitor of aberrant and hyperactive Cdk5\/p25, attenuates pathological phenotypes and restores synaptic function in CK-p25Tg mice","volume":"56","author":"Shukla","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051278","article-title":"Insights into the structure, function, and ligand discovery of the large neutral amino acid transporter 1, LAT1","volume":"19","author":"Singh","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2021.108588_bib94","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-4899-1863-5_15","article-title":"Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system","volume":"8","author":"Smith","year":"1996","journal-title":"Pharmaceut. Biotechnol."},{"issue":"4S Suppl. l","key":"10.1016\/j.neuropharm.2021.108588_bib95","doi-asserted-by":"crossref","first-page":"1016S","DOI":"10.1093\/jn\/130.4.1016S","article-title":"Transport of glutamate and other amino acids at the blood-brain barrier","volume":"130","author":"Smith","year":"2000","journal-title":"J. Nutr."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108588_bib96","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/j.1471-4159.1987.tb01039.x","article-title":"Kinetics of neutral amino acid transport across the blood-brain barrier","volume":"49","author":"Smith","year":"1987","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib97","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pscychresns.2008.04.003","article-title":"Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study","volume":"171","author":"Starr","year":"2009","journal-title":"Psychiatr. Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108588_bib98","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1111\/j.0953-816X.2004.03365.x","article-title":"Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain","volume":"19","author":"Swatton","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jalz.2018.07.222","article-title":"Vascular dysfunction-The disregarded partner of Alzheimer's disease","volume":"15","author":"Sweeney","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2021.108588_bib100","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejps.2018.02.005","article-title":"High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier","volume":"117","author":"Taccola","year":"2018","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"3 Pt 2","key":"10.1016\/j.neuropharm.2021.108588_bib101","first-page":"H484","article-title":"An in situ brain perfusion technique to study cerebrovascular transport in the rat","volume":"247","author":"Takasato","year":"1984","journal-title":"Am. J. Physiol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2021.108588_bib102","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-3940(01)01864-X","article-title":"Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain","volume":"306","author":"Takashima","year":"2001","journal-title":"Neurosci. Lett."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108588_bib103","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1177\/0271678X17722436","article-title":"The vascular basement membrane in the healthy and pathological brain","volume":"37","author":"Thomsen","year":"2017","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2021.108588_bib104","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0014-5793(02)02934-4","article-title":"A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains","volume":"523","author":"Tseng","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2021.108588_bib105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fnagi.2020.00080","article-title":"Brain microvascular pericytes in vascular cognitive impairment and dementia","volume":"12","author":"Uemura","year":"2020","journal-title":"Front. Aging Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib106","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuron.2015.10.008","article-title":"Re-evaluation of the blood-brain barrier in the presence of alzheimer's disease pathology","volume":"88","author":"Ulrich","year":"2015","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108588_bib107","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1148\/radiol.2016152244","article-title":"Blood-brain barrier leakage in patients with early alzheimer disease","volume":"281","author":"van de Haar","year":"2016","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108588_bib108","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jmri.20669","article-title":"Vascular volume and blood-brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls","volume":"24","author":"Wang","year":"2006","journal-title":"J. Magn. Reson. Imag."},{"key":"10.1016\/j.neuropharm.2021.108588_bib109","first-page":"12","article-title":"Selective neuronal vulnerability to oxidative stress in the brain","volume":"2","author":"Wang","year":"2010","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108588_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2006.11.089","article-title":"Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy","volume":"1134","author":"Yousif","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108588_bib111","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1749-6632.1997.tb48467.x","article-title":"Vascular basement membrane pathology and Alzheimer's disease","volume":"826","author":"Zarow","year":"1997","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"30","key":"10.1016\/j.neuropharm.2021.108588_bib112","doi-asserted-by":"crossref","first-page":"22042","DOI":"10.1074\/jbc.M112.436402","article-title":"Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models","volume":"288","author":"Zhang","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108588_bib113","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.neurobiolaging.2006.05.016","article-title":"Microvascular injury and blood-brain barrier leakage in Alzheimer's disease","volume":"28","author":"Zipser","year":"2007","journal-title":"Neurobiol. Aging"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108588_bib114","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.tins.2005.02.001","article-title":"Neurovascular mechanisms of Alzheimer's neurodegeneration","volume":"28","author":"Zlokovic","year":"2005","journal-title":"Trends Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108588_bib115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:10:49Z","timestamp":1758438649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821001428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":117,"alternative-id":["S0028390821001428"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108588","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108588"}}